Uzbekistan is set to upgrade two major substations in Tashkent through a new contract with a Chinese company. The project ...

ASCO 2025 may be over, but the insights are just beginning. This “Spotlight On” page is your hub for ongoing post-event coverage, including expert interviews, key takeaways, and video content ...

ASCO: TIGIT returns with Roche, Gilead data A year ago, enthusiasm for a new generation of cancer immunotherapies targeting TIGIT started to wane, after Roche’s tiragolumab was hit by two failed ...

ASCO 2025 phase 1b/2 study assessing 9MW2821, nectin-4 antibody drug conjugate, toripalimab in treatment-naïve patients, locally advanced or metastatic urothelial carcinoma.